Trinity Biotech Commences Sales of Five Newly FDA-Approved Products
June 4, 1997 08:26 AM
DUBLIN, Ireland, June 4 /PRNewswire/ -- Trinity Biotech plc TRIBY today announced that it has
begun shipping five new products that have recently received marketing approval from the U.S. Food
and Drug Administration. These products, Lyme IgG, Lyme IgG/IgM, Legionella, Chlamydia IgG and
Herpes Group Antigen, are all in the micro-titre Enzyme Immunoassay ("EIA") format. The products
are being shipped to Wampole Laboratories, a division of Carter-Wallace, Inc. CAR , with which
Trinity has an exclusive supply agreement for micro-titre based EIA tests in the U.S. The products are
manufactured in Trinity's Jamestown, NY facility, which has both ISO 9001 and FDA registration. |
